Drug Ther Bull. 2012 Dec;50(12):141-4. doi: 10.1136/dtb.2012.11.0150.
Multiple sclerosis (MS) is a neurological condition that is estimated to affect around 60,000 people in England and Wales, with a lifetime risk in the UK of 1 in 1,000.(1,2) Spasticity (an increase in muscle tone) is a common symptom of MS, resulting in muscle spasms, immobility, disturbed sleep and pain.(3,4) Complex drug combinations are sometimes necessary to manage symptoms of MS, but these are often only partially effective and associated with unacceptable side effects.(5) Cannabis extract containing delta9-tetrahydrocannabinol (dronabinol) and cannabidiol are the principal extracts from the cannabis plant present in a licensed preparation (▾Sativex - GW Pharma Ltd), the first cannabinoid preparation to be approved for medical use. Sativex has been licensed "for symptom improvement in adult patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy".(6) Here we review the evidence for cannabis extract and its place in the treatment of the condition.
多发性硬化症（MS）是一种神经系统疾病，据估计在英格兰和威尔士约有6万人受其影响，在英国终生患病风险为千分之一。（1,2）痉挛（肌张力增加）是MS的常见症状，会导致肌肉痉挛、行动不便、睡眠障碍和疼痛。（3,4）有时需要使用复杂的药物组合来控制MS症状，但这些药物往往效果不佳，且伴有难以接受的副作用。（5）含有δ9-四氢大麻酚（屈大麻酚）和大麻二酚的大麻提取物是一种已获许可制剂（▾ 萨替维克斯 - GW制药有限公司）中存在的大麻植物的主要提取物，这是首个获批用于医疗用途的大麻素制剂。萨替维克斯已获批“用于改善成年MS患者的中度至重度痉挛症状，这些患者对其他抗痉挛药物反应不佳，且在初始治疗试验期间痉挛相关症状有临床显著改善”。（6）在此，我们综述大麻提取物的证据及其在该疾病治疗中的地位。
